The Chick Chorioallantoic Membrane As an in Vivo Xenograft Model for Burkitt Lymphoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Jun 3

PMID 24884418

Citations 24

Authors

Marcel Klingenberg

Jurgen Becker

Sonja Eberth

Dieter Kube

Jorg Wilting

Affiliations

Soon will be listed here.

Abstract

Background: Burkitt lymphoma (BL) is an aggressive malignancy that arises from B-cells and belongs to the group of Non-Hodgkin lymphomas (NHL). Due to the lack of appropriate in vivo models NHL research is mainly performed in vitro. Here, we studied the use of the chick chorioallantoic membrane (CAM) for the generation of human BL xenograft tumors, which we compared with known characteristics of the human disease.

Methods: In order to generate experimental BL tumors, we inoculated human BL2B95 and BL2-GFP cells on the CAM. BL2B95 xenograft-tumors were grown for seven days and subsequently analyzed with transmission electron and immunofluorescence microscopy, as well as histological staining approaches. BL2-GFP cells were studied at regular intervals up to seven days, and their metastatic behavior was visualized with intravital immunofluorescence techniques.

Results: Xenografted BL2B95 cells formed solid tumors in the CAM model with a Ki67-index greater than 90%, preservation of typical tumor markers (CD10, CD19, CD20), a 'starry sky' morphology, production of agyrophilic fibers in the stroma, formation of blood and lymphatic vessels and lymphogenic dissemination of BL2B95 to distant sites. We identified macrophages, lymphocytes and heterophilic granulocytes (chick homolog of neutrophils) as the most abundant immune cells in the experimental tumors. BL2-GFP cells could be traced in real-time during their distribution in the CAM, and the first signs for their dissemination were visible after 2-3 days.

Conclusions: We show that xenografted BL2B95 cells generate tumors in the CAM with a high degree of cellular, molecular and proliferative concord with the human disease, supporting the application of the CAM model for NHL research with a focus on tumor-stroma interactions. Additionally we report that BL2-GFP cells, grafted on the CAM of ex ovo cultured chick embryos, provide a powerful tool to study lymphogenic dissemination in real-time.

Citing Articles

G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy.

Ribeiro M, Profitos-Peleja N, Santos J, Blecua P, Reyes-Garau D, Armengol M Front Immunol. 2023; 14:1130052.

PMID: 37153563 PMC: 10160608. DOI: 10.3389/fimmu.2023.1130052.

CAM-Xenograft Model Provides Preclinical Evidence for the Applicability of [Ga]Ga-Pentixafor in CRC Imaging.

Bencurova K, Friske J, Anderla M, Mayrhofer M, Wanek T, Nics L Cancers (Basel). 2022; 14(22).

PMID: 36428644 PMC: 9688097. DOI: 10.3390/cancers14225549.

A Face-To-Face Comparison of Tumor Chicken Chorioallantoic Membrane (TCAM) In Ovo with Murine Models for Early Evaluation of Cancer Therapy and Early Drug Toxicity.

Rupp T, Legrand C, Hunault M, Genest L, Babin D, Froget G Cancers (Basel). 2022; 14(14).

PMID: 35884608 PMC: 9325108. DOI: 10.3390/cancers14143548.

Curcumin, thymoquinone, and 3, 3'-diindolylmethane combinations attenuate lung and liver cancers progression.

Saddiq A, El-Far A, Mohamed Abdullah S, Godugu K, Almaghrabi O, Mousa S Front Pharmacol. 2022; 13:936996.

PMID: 35847018 PMC: 9277483. DOI: 10.3389/fphar.2022.936996.

Proteomic Analysis of Chicken Chorioallantoic Membrane (CAM) during Embryonic Development Provides Functional Insight.

Ahmed T, Cordeiro C, Elebute O, Hincke M Biomed Res Int. 2022; 2022:7813921.

PMID: 35774275 PMC: 9237712. DOI: 10.1155/2022/7813921.

References

Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J . Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011; 30(1):83-95. DOI: 10.1007/s10555-011-9281-4. View

Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H . Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol. 2002; 20(22):4413-9. DOI: 10.1200/JCO.2002.07.075. View

Forteza-Vila J, Fraga M . Burkitt lymphoma and diffuse aggressive B-cell lymphoma. Int J Surg Pathol. 2010; 18(3 Suppl):133S-135S. DOI: 10.1177/1066896910370614. View

Wilting J, Birkenhager R, Eichmann A, Kurz H, Martiny-Baron G, Marme D . VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Dev Biol. 1996; 176(1):76-85. DOI: 10.1006/dbio.1996.9993. View

BURKITT D . A sarcoma involving the jaws in African children. Br J Surg. 1958; 46(197):218-23. DOI: 10.1002/bjs.18004619704. View

BURKITT D, OCONOR G . Malignant lymphoma in African children. I. A clinical syndrome. Cancer. 1961; 14:258-69. DOI: 10.1002/1097-0142(196103/04)14:2<258::aid-cncr2820140206>3.0.co;2-7. View

Zijlstra A, Seandel M, Kupriyanova T, Partridge J, Madsen M, Hahn-Dantona E . Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells. Blood. 2005; 107(1):317-27. PMC: 1895349. DOI: 10.1182/blood-2005-04-1458. View

De Saint-Hubert M, Brepoels L, Devos E, Vermaelen P, Groot T, Tousseyn T . Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition. Am J Nucl Med Mol Imaging. 2012; 2(1):110-21. PMC: 3478112. View

Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L . Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One. 2010; 5(6):e11140. PMC: 2886845. DOI: 10.1371/journal.pone.0011140. View

10.

Wright D . Cytology and histochemistry of the Burkitt lymphoma. Br J Cancer. 1963; 17:50-5. PMC: 2071294. DOI: 10.1038/bjc.1963.7. View

11.

Ganor Y, Grinberg I, Reis A, Cooper I, Goldstein R, Levite M . Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo. Leuk Lymphoma. 2009; 50(6):985-97. DOI: 10.1080/10428190902878448. View

12.

Morton L, Wang S, Devesa S, Hartge P, Weisenburger D, Linet M . Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2005; 107(1):265-76. PMC: 1895348. DOI: 10.1182/blood-2005-06-2508. View

13.

Ogden C, Pound J, Batth B, Owens S, Johannessen I, Wood K . Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol. 2005; 174(5):3015-23. DOI: 10.4049/jimmunol.174.5.3015. View

14.

Crivellato E, Nico B, Vacca A, Ribatti D . B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization. Haematologica. 2003; 88(6):671-8. View

15.

Lokman N, Elder A, Ricciardelli C, Oehler M . Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. Int J Mol Sci. 2012; 13(8):9959-9970. PMC: 3431839. DOI: 10.3390/ijms13089959. View

16.

Ribatti D, Vacca A, Bertossi M, De Benedictis G, Roncali L, Dammacco F . Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype. Anticancer Res. 1990; 10(2A):401-6. View

17.

Jaffe E, Pittaluga S . Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program. 2011; 2011:506-14. PMC: 6329301. DOI: 10.1182/asheducation-2011.1.506. View

18.

Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F . An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des. 2008; 14(21):2023-39. DOI: 10.2174/138161208785294591. View

19.

Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley J . The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell. 2008; 13(3):221-34. PMC: 3068919. DOI: 10.1016/j.ccr.2008.01.031. View

20.

Bertrand S, Berger R, Philip T, Bernheim A, Bryon P, Bertoglio J . Variant translocation in a non endemic case of Burkitt's lymphoma: t (8;22) in an Epstein--Barr virus negative tumour and in a derived cell line. Eur J Cancer (1965). 1981; 17(5):577-84. DOI: 10.1016/0014-2964(81)90060-8. View